Neurocrine touts further positive trial results for Ingrezza

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily Ingrezza (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.

"These findings further establish Ingrezza as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying psychiatric condition, including schizophrenia, schizoaffective disorder or mood disorder," said Dr Eiry Roberts, chief medical officer of Neurocrine Biosciences. "The significant improvements observed in AIMS score and the high remission rates highlight the efficacy of Ingrezza, at even the lowest dose."

The new data come after Neurocrine’s annual results raised investor concerns over a lower-than-expected sales forecast for Ingrezza. In the fourth quarter of 2024, Ingrezza generated around $615 million in sales, slightly below analyst expectations.